Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results
PLOS One · 12.05.2026 · 21 (5) · e0349212
DOI: 10.1371/journal.pone.0349212 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.05.2026. Verfasst von Anwar Rjoop und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Microbiology, Jordan University of Science and Technology, Irbid, Jordan. Hauptthemen laut MEDLINE: Multiple Myeloma, Antigens, CD34, Hematopoietic Stem Cells, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).
Abstract (Originalsprache)
Background
Autologous stem cell transplantation remains a cornerstone of treatment for patients with transplant-eligible multiple myeloma (MM). Previous studies using gene expression profiling (GEP) have classified MM into seven molecular subgroups: HY, CD-1, CD-2, LB, PR, MS, and MF. Together with GEP signature, it can help identify patients with better or worse outcomes. In this study, we wanted to study how these molecular subtypes, along with cytogenetics, FISH results, and different treatment regimens, relate to the count of CD34 + hematopoietic progenitor cells (HPC) collected during stem cell mobilization.
Methods
We conducted a retrospective study of 505 MM patients who underwent hematopoietic progenitor cell (HPC) collection between January 2017 and December 2020. Demographic, molecular (FISH, cytogenetics, GEP), clinical, treatment, and mobilization regimen data were collected and analyzed to determine factors influencing CD34 + HPC yield.
Results
Factors associated with reduced CD34 + HPC collection included PR and MF GEP subtypes, deletion 13 (−13), and high-risk genetic classification. In contrast, normal versus abnormal karyotype, hyperdiploid versus hypodiploid karyotype, and the use of either proteasome inhibitors in combination with heterogeneous chemotherapy regimens did not significantly impact CD34 + HPC yield.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Microbiology, Jordan University of Science and Technology, Irbid, Jordan.
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
- Department of General Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
- Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
- Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
ORCID-Profile: Anwar Rjoop, Daoud O Al Aruri
Zitieren
APA
Rjoop, A., Perez, I., Al Aruri, D. O., AlBarakat, M. M., van Rhee, F., & Drobena, G. (2026). Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results. PLOS One, 21(5), e0349212. https://doi.org/10.1371/journal.pone.0349212
Vancouver
Rjoop A, Perez I, Al Aruri DO, AlBarakat MM, van Rhee F, Drobena G. Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results. PLOS One. 2026;21(5):e0349212. doi:10.1371/journal.pone.0349212
BibTeX
@article{Rjoop2026,
author = {Rjoop, Anwar and Perez, Ivette and Al Aruri, Daoud O and AlBarakat, Majd M and van Rhee, Frits and Drobena, Gina},
title = {Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0349212},
doi = {10.1371/journal.pone.0349212}
}
EUVIMED